Does Rallies show 13F holders for ALNY?

Yes. Rallies tracks hedge fund and 13F ownership data for ALNY, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ALNY research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ALNY. It does not provide personalized investment advice.

ALNY (Alnylam Pharmaceuticals) Stock Analysis - Hedge Fund Holdings

Alnylam Pharmaceuticals (ALNY) is a publicly traded Healthcare sector company. As of May 20, 2026, ALNY trades at $295.43 with a market cap of $38.22B and a P/E ratio of 122.46. ALNY moved +1.41% today. Year to date, ALNY is -24.97%; over the trailing twelve months it is +2.33%. Its 52-week range spans $205.87 to $495.55. Analyst consensus is strong buy with an average price target of $452.73. Rallies surfaces ALNY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ALNY stock?

Hedge funds tracked by Rallies that own ALNY include Orbimed Advisors, Bridgewater Associates, Panagora Asset, Soros Fund, and Bluecrest Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Alnylam Pharmaceuticals.

ALNY Key Metrics

Key financial metrics for ALNY
Metric	Value
Price	$295.43
Market Cap	$38.22B
P/E Ratio	122.46
EPS	$2.39
Dividend Yield	0.00%
52-Week High	$495.55
52-Week Low	$205.87
Volume	603.28K
Avg Volume	0
Revenue (TTM)	$3.71B
Net Income	$313.75M
Gross Margin	81.77%

Top Hedge Funds Holding ALNY

Orbimed Advisors holds 119.00K shares of ALNY, changed -58.80% as of Mar 31, 2026.
Bridgewater Associates holds 106.59K shares of ALNY, changed +24.50% as of Mar 31, 2026.
Panagora Asset holds 10.34K shares of ALNY, changed -66.47% as of Mar 31, 2026.
Soros Fund holds 4.29K shares of ALNY, changed -92.84% as of Sep 30, 2025.
Bluecrest Capital holds 1.23K shares of ALNY, changed +0.00% as of Sep 30, 2025.

Latest ALNY News

Alnylam slips after Q1 results despite $1.04B product revenue and guidance reiteration — May 1, 2026
Alnylam jumps as Q1 profit and record $1.17B revenue top expectations — Apr 30, 2026
Alnylam slides as traders de-risk into April 30 Q1 results, valuation worries linger — Apr 24, 2026
Alnylam drops as Jefferies downgrade spotlights valuation after big run — Apr 19, 2026
Alnylam slides as valuation worries persist after Jefferies downgrade and target cut — Apr 18, 2026

Recent ALNY Insider Trades

McLaughlin Melissa sold 56 (~$17.93K) on Apr 6, 2026.
McLaughlin Melissa sold 909 (~$299.75K) on Apr 6, 2026.
McLaughlin Melissa sold 829 (~$273.95K) on Apr 6, 2026.

ALNY Analyst Consensus

18 analysts cover ALNY: 0 strong buy, 15 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $452.73.

Common questions about ALNY

Who owns ALNY stock?: Hedge funds tracked by Rallies that own ALNY include Orbimed Advisors, Bridgewater Associates, Panagora Asset, Soros Fund, and Bluecrest Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Alnylam Pharmaceuticals.
Does Rallies show 13F holders for ALNY?: Yes. Rallies tracks hedge fund and 13F ownership data for ALNY, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ALNY research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ALNY. It does not provide personalized investment advice.